8cyh: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
New page: '''Unreleased structure''' The entry 8cyh is ON HOLD Authors: Bandaranayake, A.D., Rupert, P.B., Lin, I., Pilat, K., Ruff, R.O., Friend, D.J., Chan, M.K., Clarke, M., Carter, J., Meshin...
 
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Unreleased structure'''


The entry 8cyh is ON HOLD
==Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics==
 
<StructureSection load='8cyh' size='340' side='right'caption='[[8cyh]], [[Resolution|resolution]] 3.38&Aring;' scene=''>
Authors: Bandaranayake, A.D., Rupert, P.B., Lin, I., Pilat, K., Ruff, R.O., Friend, D.J., Chan, M.K., Clarke, M., Carter, J., Meshinchi, S., Mehlin, C., Olson, J.M., Strong, R.K., Correnti, C.E.
== Structural highlights ==
 
<table><tr><td colspan='2'>[[8cyh]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8CYH OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8CYH FirstGlance]. <br>
Description: Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo-main and Engineering of Potent, T cell-engaging Bispecific Therapeutics
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.38&#8491;</td></tr>
[[Category: Unreleased Structures]]
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
[[Category: Olson, J.M]]
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8cyh FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8cyh OCA], [https://pdbe.org/8cyh PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8cyh RCSB], [https://www.ebi.ac.uk/pdbsum/8cyh PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8cyh ProSAT]</span></td></tr>
[[Category: Ruff, R.O]]
</table>
[[Category: Lin, I]]
== Disease ==
[[Category: Rupert, P.B]]
[https://www.uniprot.org/uniprot/MSLN_HUMAN MSLN_HUMAN] Antibodies against MSLN are detected in patients with mesothelioma and ovarian cancer.
[[Category: Bandaranayake, A.D]]
== Function ==
[[Category: Pilat, K]]
[https://www.uniprot.org/uniprot/MSLN_HUMAN MSLN_HUMAN] Membrane-anchored forms may play a role in cellular adhesion.<ref>PMID:8288629</ref> <ref>PMID:14676194</ref>  Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro.<ref>PMID:8288629</ref> <ref>PMID:14676194</ref>
[[Category: Mehlin, C]]
== References ==
[[Category: Strong, R.K]]
<references/>
[[Category: Clarke, M]]
__TOC__
[[Category: Chan, M.K]]
</StructureSection>
[[Category: Friend, D.J]]
[[Category: Homo sapiens]]
[[Category: Carter, J]]
[[Category: Large Structures]]
[[Category: Correnti, C.E]]
[[Category: Bandaranayake AD]]
[[Category: Meshinchi, S]]
[[Category: Carter J]]
[[Category: Chan MK]]
[[Category: Clarke M]]
[[Category: Correnti CE]]
[[Category: Friend DJ]]
[[Category: Lin I]]
[[Category: Mehlin C]]
[[Category: Meshinchi S]]
[[Category: Olson JM]]
[[Category: Pilat K]]
[[Category: Ruff RO]]
[[Category: Rupert PB]]
[[Category: Strong RK]]

Latest revision as of 13:04, 25 October 2023

Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific TherapeuticsNovel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics

Structural highlights

8cyh is a 3 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 3.38Å
Ligands:
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Disease

MSLN_HUMAN Antibodies against MSLN are detected in patients with mesothelioma and ovarian cancer.

Function

MSLN_HUMAN Membrane-anchored forms may play a role in cellular adhesion.[1] [2] Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro.[3] [4]

References

  1. Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994 Jan 14;269(2):805-8. PMID:8288629
  2. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004 Mar 5;279(10):9190-8. Epub 2003 Dec 15. PMID:14676194 doi:http://dx.doi.org/10.1074/jbc.M312372200
  3. Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994 Jan 14;269(2):805-8. PMID:8288629
  4. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004 Mar 5;279(10):9190-8. Epub 2003 Dec 15. PMID:14676194 doi:http://dx.doi.org/10.1074/jbc.M312372200

8cyh, resolution 3.38Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA